Sandu Pharmaceuticals (524703) Q1 26/27 earnings summary

Executive summary

• Unaudited standalone financial results for the quarter ended June 30, 2026, were approved, with the auditor expressing an unmodified conclusion on the review.

• Directors' Report, Management Discussion and Analysis, and other annual reports for FY 2025-26 were approved for the upcoming AGM.

• The 41st AGM is scheduled for September 11, 2026, via video conferencing.

Financial highlights

• Revenue from operations for Q1 FY27 was ₹1,638.88 lakhs, compared to ₹1,669.90 lakhs in Q1 FY26 and ₹1,685.34 lakhs in Q4 FY26.

• Profit before tax for Q1 FY27 was ₹36.05 lakhs, up from ₹33.87 lakhs in Q1 FY26 but down from ₹74.71 lakhs in Q4 FY26.

• Net profit for Q1 FY27 stood at ₹22.82 lakhs, compared to ₹22.33 lakhs in Q1 FY26 and ₹4.34 lakhs in Q4 FY26.

• Total comprehensive income for Q1 FY27 was ₹38.35 lakhs, versus ₹32.66 lakhs in Q1 FY26 and ₹70.68 lakhs in Q4 FY26.

• Basic and diluted EPS for Q1 FY27 was ₹0.37, compared to ₹0.23 in Q1 FY26 and ₹0.04 in Q4 FY26.

Outlook and guidance

• The Board approved the closure of the Register of Members and Share Transfer Books from September 4 to September 11, 2026, with September 4 as the record date for dividend eligibility.